Figure 2
From: MiRNA-125a-5p: a regulator and predictor of gefitinib’s effect on nasopharyngeal carcinoma
Gefitinib-mediated inhibition of tumor growth. Mice were treated by gavage with NS or gefitinib (70 mg/kg/day) every day for 14 days. (A). Antitumor efficacy of gefitinib in HNE-1 (n = 5/group) and HK-1 (n = 5/group) models. The results are expressed as the mean volume ± SD. (B). Two representative athymic nude mice from the NS-treated and gefitinib-treated groups are shown. (C). Antitumor efficacy of gefitinib presented by tumor weight in the two models. The results are expressed as the mean weight ± SD.* P < 0.05.